CanBas Co., Ltd. (4575.T)
JPY 957.0
(-2.35%)
JPY 957.0
(-2.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 53.65 Million JPY | 1.55% |
| 2022 | -1.24 Billion JPY | -51.05% |
| 2021 | -848.64 Million JPY | -54.97% |
| 2020 | -522.28 Million JPY | 3.71% |
| 2019 | -566.54 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -707.42 Million JPY | -343.24% |
| 2023 Q1 | -194.49 Million JPY | 66.02% |
| 2023 FY | - JPY | 1.55% |
| 2023 Q3 | -159.6 Million JPY | 19.73% |
| 2023 Q2 | -198.84 Million JPY | -2.23% |
| 2022 Q2 | -238.46 Million JPY | 23.83% |
| 2022 FY | - JPY | -51.05% |
| 2022 Q4 | -572.38 Million JPY | -286.78% |
| 2022 Q3 | -147.98 Million JPY | 37.94% |
| 2022 Q1 | -313.07 Million JPY | 0.0% |
| 2021 FY | - JPY | -54.97% |
| 2020 FY | - JPY | 3.71% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 94.4% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 110.991% |
| GNI Group Ltd. | 14.48 Billion JPY | 99.63% |
| Linical Co., Ltd. | 1.24 Billion JPY | 95.698% |
| Trans Genic Inc. | 240.95 Million JPY | 77.734% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 103.957% |
| Soiken Holdings Inc. | -583.2 Million JPY | 109.199% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 108.896% |
| AnGes, Inc. | -8.86 Billion JPY | 100.606% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 104.174% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 100.725% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 58.12% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 106.217% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 104.914% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 106.917% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 147.988% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 104.428% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 103.885% |
| PeptiDream Inc. | 7.37 Billion JPY | 99.273% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 102.78% |
| Ribomic Inc. | -1.01 Billion JPY | 105.299% |
| SanBio Company Limited | -4.52 Billion JPY | 101.186% |
| Healios K.K. | -3 Billion JPY | 101.784% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 104.602% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 103.851% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 103.827% |
| StemRIM | -2.03 Billion JPY | 102.64% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 95.893% |
| FunPep Company Limited | -952 Million JPY | 105.636% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 106.037% |
| Stella Pharma Corporation | -723.85 Million JPY | 107.412% |
| TMS Co., Ltd. | -937 Million JPY | 105.726% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 106.919% |
| Cuorips Inc. | -518 Million JPY | 110.357% |
| K Pharma,Inc. | 366.05 Million JPY | 85.344% |
| Takara Bio Inc. | 8.02 Billion JPY | 99.331% |
| ReproCELL Incorporated | 8.24 Million JPY | -550.71% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 38.99% |
| StemCell Institute Inc. | 534.35 Million JPY | 89.96% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 78.085% |
| CellSeed Inc. | -836.51 Million JPY | 106.414% |